Interferon alpha-2a and 13-cis-retinoic acid in patients with metastatic renal cell cancer

Cancer Investigation

Volumn 18, Issue 5, 2000, Pages 417-421

  Jacobs, Andrew ^a   Gold, Philip ^b   Weiden, Paul ^a   Aboulafia, David ^a   Rudolph, Robert ^a   Picozzi, Vincent ^a   Thompson, John ^b  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN; RECOMBINANT ALPHA2A INTERFERON;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CHEILITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; INFLUENZA; KIDNEY CANCER; KIDNEY METASTASIS; MALE; NEPHRECTOMY; OUTPATIENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0034038715     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357900009032812     Document Type: Article

References (26)

1. Parker SL, Tong T, Bolden S, et al.: Cancer statistics. CA Cancer J Clinicians 47:5-27, 1997.
2. Linehan WM, Shipley WU, Parkinson DR: Renal carcinoma. In: Cancer Principles and Practice of Oncology, 5th ed., edited by VT DeVita Jr, S Hellman, SA Rosenberg, Philadelphia, Lippincott-Raven, 1997, pp. 1271-1280.
3. Umeda T, Niijima T: Phase II study of alpha interferon on renal cell carcinoma: summary of three collaborative trials. Cancer 58:1231-1235, 1986.
4. Minasian LM, Motzer RJ, Gluck L, et al.: Interferon alpha-2a in advanced renal cell carcinoma. J Clin Oncol 11:1368-1375, 1993.
5. deKernion J, Sarna G, Figlin R, et al.: The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J Urol 130:1063-1066, 1983.
6. Quesada JR, Swanson DA, Trindale A, et al.: Renal cell carcinoma; anti-tumor effects of alpha-interferon. Cancer Res 43:940-947, 1983.
7. Quesada JR, Swanson DA, Gutterman JU: Phase II study of interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 3: 1086-1092, 1985.
8. Kirkwood JM, Harris JE, Vera R, et al.: Randomized study of low and high doses of leukocyte alpha interferon in metastatic renal cell carcinoma. Cancer Res 45:863-871, 1985.
9. Figlin RA, deKernion JB, Mukamel E, et al.: Recombinant interferon alpha-2a in metastatic renal cell carcinoma. J Clin Oncol 6: 1604-1610, 1988.
10. Neidhart JA, Gagen MM, Young D, et al.: Interferon-alpha treatment of renal cell cancer. Cancer Res 44:4140-4143, 1994.
11. Lippman SM, Parkinson DR, Itri LM, et al.: 13-cis-Retinoic acid and interferon-alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84:235-241, 1992.
12. Lippman SM, Cavanagh JJ, Paredes-Espinoza M, et al.: 13-cis-Retinoic acid plus interferon-alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 84:241-245, 1992.
13. Motzer RJ, Schwartz L, Law TM, et al.: Interferon alpha-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 13:1950-1957, 1995.
14. Miller AB, Hoogstraten B, Staquet M: Reporting results of cancer treatment. Cancer 47:207-214, 1981.
15. Gehan EA: The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13:346-353, 1961.
16. Berg WJ, Schwartz LH, Amsterdam A, et al.: A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma. Invest New Drugs 15:353-355, 1997.
17. Leung ACF, Nanus DM, Mamazumdar M, et al.: Retinoic acid receptor-β (RAR-β) expression in renal cell carcinoma (RCC) of patients treated with interferon-alfa-2a (IFN) and 13-cis-retinoic acid (CRA): correlation with clinical response. Proc ASCO 16:1203, 1997.
18. Muss HB: Interferons-clinical applications: renal cell carcinoma. In: Biologic Therapy of Cancer, editing by VT De Vita, S Hellman, SA Rosenberg, Philadelphia, J.B. Lippincott, 1991, pp. 298-311.
19. Yagoda A, Abi-Rached B, Petrylak D: Chemotherapy for advanced renal cell carcinoma: 1983-1993. Semin Oncol 22:42-60, 1995.
20. Fyfe G, Fisher RI, Rosenberg SA, et al.: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688-696, 1995.
21. Stadler WM, Vogelzang NJ: Low-dose interleukin-2 in the treatment of metastatic renal cell carcinoma. Semin Oncol 22:67-73, 1995.
22. Stadler WM, Kuzel T, Dumas M, et al.: Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal cell carcinoma. J Clin Oncol 6:1820-1825, 1998.
23. Negrier S, Escudier B, Lasset C, et al.: Recombinant human interleukin-2, recombinant human interferon-alpha-2a, or both in metastatic renal cell carcinoma. N Engl J Med 338:1272-1278, 1998.
24. Gleave M, Elhilali M, Faradet Y, et al.: Interferon-gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 338:1265-1271, 1998.
25. Bukowski M, Sharfman W, Murthy S, et al.: Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin-2 in human metastatic renal-cell carcinoma. Cancer Res 51:4199-4205, 1991.
26. Pierce W, Belldegrun A, Figlin R: Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell cancer. Semin Oncol 22:74-80, 1995.